EUPRAXIA PHARMACEUTICALS INC. Preferred Stock Dividends, Income Statement Impact
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Preferred Stock Dividends, Income Statement Impact of $2.53 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-03-13
| Period end | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|
| 2025-12-31 | $2.53M 40-F · filed 2026-03-13 |
| 2024-12-31 | $425.56K 40-F · filed 2026-03-13 |
| 2023-12-31 | $0.00 40-F · filed 2025-03-20 |